Steven Daniel Schwartz, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 17,250 shares at $33.05 ($570K) on 2015-05-08, disclosed to the SEC on 2015-05-11.
Scheduled sale ($570k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AAVL | SELL | 2015-05-22 | $648K | — | Filing → |
| AAVL | SELL | 2015-04-23 | $652K | — | Filing → |
| AAVL | SELL | 2015-04-13 | $685K | — | Filing → |